BMO Capital Maintains Market Perform on Novo Nordisk, Lowers Price Target to $40

Benzinga Newsdesk www.benzinga.com Negative 49.1%

Neg 49.1% Neu 0% Pos 0%

BMO Capital analyst Evan David Seigerman maintains Novo Nordisk (NYSE:NVO) with a Market Perform and lowers the price target from $47 to $40.